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Abstract A significant bimodal relapse hazard pattern has been observed in two in-
dependent databases for patients untreated with adjuvant chemotherapy. This im-
plies there is more than one mode of relapse. The earliest and most closely grouped
relapses occur 8e10 months after surgery for young women with node-positive dis-
ease. Analysis of these data using computer simulation suggested that surgery prob-
ably instigated angiogenesis in dormant distant disease in approximately 20% of
cases for premenopausal node-positive patients. We explore if this could explain
the mammography paradox for women aged 40e49: an unexplained temporary ex-
cess in mortality for the screened population compared to controls. Calculations
based on our data predict surgery-induced angiogenesis would accelerate disease
by a median of two years and produce 0.11 early deaths per 1000 screened young
women in the third year of screening. The predicted timing as well as the magnitude
of excess mortality agree with trial data. Surgery-induced angiogenesis could ac-
count for the mammography paradox for women aged 40e49 and the bimodal re-
lapse hazard pattern. According to the proposed biology, removing tumors could
remove the source of inhibitors of angiogenesis or growth factors could appear in re-
sponse to surgical wounding. While this needs confirmation, this could be considered
when designing treatment protocols particularly for young women with positive
nodes. It reinforces the need for close coordination between surgical resection
and ensuing medical intervention. Women need to be advised of risk of accelerated
tumor growth and early relapse before giving informed consent for mammography.
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Breast cancer is a worldwide major health concern.
While there have been reductions in mortality in
recent years, progress is far too slow. In the US in
2005 it is estimated that there will be 212,930 new
cases of breast cancer and 40,870 deaths from the
disease.1 Therapy has proven to be only partially
effective in reducing death rates with little opti-
mism until recently that major improvements are
possible. The great hope for immediate meaningful
reduction in breast cancer mortality was early de-
tection, which is known to facilitate the discovery
of breast tumors at a smaller size and with fewer
positive nodes. The probability of cure for a 1-cm
or smaller tumor and no lymph nodes involved is
approximately 90%.With the reasonable probability
that screening would detect more and more can-
cers in that or similar very early states, it was ex-
pected that mammographic screening would result
in a major reduction in breast cancer deaths.
To avoid a bias, analyses are done based on
invitation to screening rather than those who are
actually screened.2 When we discuss screening vs.
controls in this document, the proper interpreta-
tion should be invited to be screened vs. controls
who are not so invited.
As reported by eight randomized trials of breast
cancer screening initiated between 1963 and 1980,
women aged 50e59 who are screened have an
early appearing 20e30% mortality advantage com-
pared to unscreened control subjects. However,
when women aged 40e49 years are screened,
there is either no advantage or a slight disadvan-
tage for the first 6e8 years of all trials. After that,
an advantage begins to appear.3e12
When these disturbing results were first re-
ported, a mammographer was quoted to say:
‘‘You start screening and you expect to provide
a benefit, and suddenly people die at a higher
rate. Now, hold it, we’re not going out and killing
women. This demands an explanation’’.13 Pursuing
this line of thought, if more women died of breast
cancer in the screened arms than in the control
arms, the trials themselves must be spurious.
Since these trials covered the full range of the
cancer experience from randomization of a great
many (apparently) healthy subjects to ultimate
death from cancer or (much more likely) from any
other cause, there are many opportunities to
introduce bias or other errors. It was easy to
criticize these trials. These data are, however,
all we have to modulate our biases.
Following the National Institutes of Health Con-
sensus Development Conference on Breast CancerScreening for Women Ages 40e49, where all trial
data were presented, two different and contra-
dicting reports were published.14 A consensus panel
voted that data do not support a universal recom-
mendation of screening for all women aged 40e49
years and women need to be advised of risks and
benefits. A minority report came to the opposite
conclusion on the former and agreedwith the latter.
This was not well received. The director of the Na-
tional Cancer Institute criticized the majority re-
port and the US Senate voted 98-0 in a non-binding
action against it. Fletcher described these events
in a colorful comparison to Alice in Wonderland.15
The resultant controversy became even more
complicated when a later paper raised doubts
about the value of mammography screening for
women of all ages.16 Now, in the US, despite con-
flicting data, screening starts at age 40 or earlier.
In most of Europe, it starts at age 50.
It is surprising that during this heated contro-
versy, no attention was paid to the paradoxical
breast cancer mortality surge for younger women
invited to undergo screening.11 Meta-analysis of
trial data by Cox (shown in Fig. 1) indicates a mor-
tality increase in the screening arms of up to 0.15
deaths per 1000 screened subjects. That begins in
the third year (where it is maximum) and extends
to the 11th year. While the possibility that random
occurrence cannot be excluded, there is a signifi-
cant excess mortality ratio of screened to un-
screened at the 3 year point of 2.4 (1.1e5.4, 95%
CI). No other individual years show statistically sig-
nificant disadvantages as shown in Fig. 2.
Breast cancer is known as a heterogeneous
disease. What is causing apparently healthy young
women to die from breast cancer three years after
the start of screening?
Rather than a controversy, we looked upon this
situation as a scientific paradox and research op-
portunity in that data do not agree with current
theories. The scientific method instructs us to re-
examine the theory when theory and data disagree.
To help understand this paradox, we studied
relapse patterns using a breast cancer database
of 1173 pre- and postmenopausal, node-negative
and -positive patients treated with surgery only
and having 16e20 years of follow-up. This ap-
proach is relevant since at least five of the eight
screening trials began before the widespread use
of adjuvant chemotherapy in approximately 1980.
Methods and patients
All patients who from 1964 through 1980 entered
into three different clinical trials at the Milan
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treatment for operable breast cancer, were retro-
spectively evaluated. Before surgery all patients
underwent standard staging: complete physical
examination, X-ray study of chest, skull, spine,
and pelvis, bilateral mammography, ECG, complete
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Figure 1 Meta-analysis data for six screening trials for
younger women from Cox showing the cumulative breast
cancer specific mortality per screened individual and the
equivalent mortality per unscreened control. In five of
these trials the age at entry was 40e49 years and it
was 45e54 years in the other. This figure is based on
over 800,000 person-years of experience in each of the
screened and control arms. The early disadvantage to
screened young women of approximately 0.15 deaths
per 1000 screened young women is typical of results
seen in all trials. In conjunction with data shown in
Fig. 2, the significant disadvantage first appears 3 years
into the trial where it is maximum. Modified from Cox.11
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Figure 2 Yearly ratio of mortality in the screened arms
to control arms for young women as described in the
caption to Fig. 1. There are few events in the first two
years accounting for the large error spread. The dashed
line at 1.0 represents equal deaths among screened and
unscreened controls in any year. The value at 3 years is
the only point significantly different from 1.0. Data are
from Cox.11hemogram and routine biochemical tests. Primary
tumor was treated by radical or modified radical
mastectomy and no patient received postoperative
radiotherapy or chemotherapy.
Menopausal status was defined as ‘‘postmeno-
pausal’’ if one year was elapsed since the last
menstrual period. The patients were clinical pre-
sentation cases, not screening detected. The num-
ber of patients included was 1173, and of these,
520 relapsed. Median age at diagnosis was 52 years
with a range of 23e82. Distributions are shown in
Tables 1 and 2. The representation of patients in
the various tumor size and nodal groupings are sim-
ilar between pre- and postmenopausal subjects.
Results
These data on 1173 untreated early stage breast
cancer patients are mature since the follow-up is
16e20 years. Thus it can be assumed that nearly
all relapse events have occurred.17,18
Surgical cure rates grouped by tumor size and
grouped by the number of positive nodes are
shown in Table 3. There is no statistical difference
between pre- and postmenopausal patients in
their long-term prognosis as grouped by tumor
size or number of positive nodes. Thus, surgical
cure rates were independent of menopausal
status.
Relapse data are presented in Fig. 3 as the raw
number of distant relapse events grouped in serial
bins of 10-month duration. The a posteriori choice
to use 10 months as bin size resulted from a com-
parison of using bins sizes of 6, 10, 14, and 18
months. Small bin sizes show excessive noise while
Table 1 Distribution within the Milan database of
tumor size among the subsets for T1 (!2 cm diame-
ter), T2, and T3 (O5 cm diameter)
T1 T2 T3 All
Premenopausal 222 (43%) 264 (51%) 30 (6%) 516
Postmenopausal 237 (36%) 364 (55%) 56 (9%) 657
All patients 459 (39%) 628 (54%) 86 (7%) 1173
Table 2 Distribution of nodal status among the
subsets
NZ 0 NZ 1e3 NO 3 All
Premenopausal 265 (51%) 158 (31%) 93 (18%) 516
Postmenopausal 333 (51%) 184 (28%) 140 (21%) 657
All patients 598 (51%) 342 (29%) 233 (20%) 1173
182 M. Retsky et al.Table 3 Percentage of patients who eventually relapsed in the mature NZ 1173 Milan database grouped by
tumor size and by the number of positive lymph nodes for pre- and postmenopausal patients
T1 (%) T2 (%) T3 (%) NZ 0 (%) NZ 1e3 (%) NO 3 (%)
Premenopausal 41 60 70 30 66 84
Postmenopausal 38 56 62 25 66 84
From a difference of proportions hypothesis test, in each case and overall, there is no statistically significant difference between
the two menopausal states in cure rates. Thus if a patient had x nodes positive and y tumor size, the long-term relapse probability
was independent of menopausal status.large bin sizes tend to mask structure. Ten-month
bins were chosen to optimize the display of struc-
ture in the time dependent data.
The frequency of relapse has a double-peaked
distribution. There is a sharp peak at 18 months,
a nadir at 50 months and a broad peak at 60
months with a long tail extending to 15e20 years.
Patients with larger tumors more frequently re-
lapse in the first peak while those with smaller
tumors relapse equally in both peaks. Specifically,
for T1 tumors (!2 cm diameter) 50% of all relapses
are in the first peak, for T2 tumors 75% of relapses
are in the first peak, and for T3 tumors (O5 cm di-
ameter) 83% are in the first peak.
When we compared these temporal relapse data
between premenopausal patients and postmeno-
pausal patients, the relapse pattern differed
markedly but only in the initial period following
resection and particularly so for patients with
positive axillary lymph node involvement.19 That
is, the temporal relapse pattern had menopausal
status dependent features. In premenopausal pa-
tients with node-positive disease, 20% relapsed
within the first 10 months following resection.
That is a far higher percentage than for any other
grouping. For comparison, in that first 10-month
period, the relapse rate was five times higher for
node-positive patients as node-negative patients.
140
120
100
80
60
40
20
0
0 20 40 60 80 100 120 140 160 180 200
Fr
eq
ue
nc
y
Months from surgery to first recurrence
Figure 3 Milan database relapse frequency for distant
plus local relapses. Data are grouped in 10-month wide
bins.Also in that same period, the relapse rate was
twice as high for premenopausal as postmeno-
pausal patients. So the high frequency of relapse
in the first 10 months after surgery was mainly pe-
culiar to premenopausal node-positive patients.
See Table 4 for more details.
The Milan data are shown in Fig. 4 in the more
usual disease-free-survival format. A subtle flat-
tening at 4 years marks the nadir between the
two peaks. That might explain why the bimodal
pattern could be so often overlooked. While we
have not conducted a thorough literature search,
bimodal relapse patterns similar to what is seen
in Figs. 3 and 4 have been identified in some
(but not all) disease-free survival and hazard of
relapse databases for untreated patients.20e26 A
recent study using a San Antonio database that is
larger than the Milan database reported that a sta-
tistically significant bimodal relapse distribution is
identified with similar features.27 However, using
a third database from Villejiuf, another analysis re-
ported no such bimodal pattern.28 All three data-
bases were tested using different methodologies.
From our perspective all these data are not too dis-
similar. We have initiated a collaborative project to
repeat these studies but with common
methodologies.
Predictions from our previously reported com-
puter simulation of the Milan bimodal relapse data
are that breast cancer growth often includes
periods of temporary dormancy. This is consistent
with many reports.29e38 The second peak is the
Table 4 Percentage of all distant relapses that
occur in the first 10 months after surgery in Milan
database
0 nodes
positive (%)
1e3 nodes
positive (%)
O3 nodes
positive (%)
Premenopausal 4 26 28
Postmenopausal 6 12 18
These very early relapses are associated with premenopausal
status and positive nodes.
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sult from steady stochastic transitions from single
cells (dormancy half-life of 1 year) progressing to
an avascular micrometastasis (dormancy half-life
of 2 years) to a growing lesion that eventually be-
comes detected as a relapse.
The top of the second peak (at 60 months)
marks when the benefit of surgery is first seen.
That is, the time that it takes a newly seeded
malignant cell to become a detectable lesion is so
long that the benefit of surgery, that stops the
seeding process, does not appear as a reduction in
relapses until 5 years have passed in a patient
population. This process may be thought of as
a metastatic pipeline that is so long that it is fully 5
years after the entrance spigot is turned off before
the pipeline is depleted. The first peak is too sharp
to be the result of steady stochastic transitions.
Some breaking of dormancy had to occur at surgery
to explain the first peak. The computer simulation
results are shown in Fig. 5 superimposed on the
data already shown in Fig. 3.
Two previously unreported surgery-accelerated
relapse modes comprise the dominant first peak.
This is consistent with some reports for animal
models and human cancer.36e41 In the first 10
months, there are relapses due to avascular micro-
metastases (preexisting at primary tumor detec-
tion) that are stimulated to vascularize at
surgery. This mode is prominent only for premeno-
pausal node-positive patients in which case over
20% of patients relapse in this manner. The remain-
der of events in the first peak are single cells that
are dormant at primary detection and are induced
to divide as a result of surgery. These then must
undergo a stochastic transition to an eventual
Figure 4 The same data as shown in Fig. 3 but pre-
sented in disease-free survival format. The 50-month
nadir from Fig. 3 appears as a subtle flattening of dis-
ease-free survival before the relapses increase again at
the 5-year point. Modified from Bonadonna et al.59growing metastasis. This mode is very common e
occurring for 50e83% of relapsing patients increas-
ing with tumor size but independent of age.
With this theoretical insight from the computer
simulation studies, we turned our attention to the
trials of early detection of breast cancer. Mam-
mography screening was first studied in a large
randomized controlled trial in New York (the
Health Insurance Plan of Greater New York or HIP
trial) in the 1960s3 and was further assessed in
other randomized trials (Malmo, Two-County,
Stockholm, Goteborg) in Sweden in the 1970s and
1980s.4e6 The Swedish trials (excluding a Kop-
parberg segment of the Two-County study) have
been recently reviewed by an Overview Commit-
tee that confirmed fundamentally the results pre-
viously reported by the individual research
groups.42 Even the results of a UK trial (Edinburgh)
were quite similar although this trial has been crit-
icized for a randomization bias.7,43 Trial results for
the New York, Swedish overview and Edinburgh tri-
als are shown in Figs. 6e8.
As already stated, computer simulation suggests
that the removal of a primary breast tumor from
premenopausal node-positive women triggers the
growth of temporarily dormant distant micrometa-
stases in approximately 20% of cases. Since the
yield is relatively high at the initial screen in
a previously unscreened population, such relapses
would appear prominently in a screening trial
within 1 year after the start of screening. However,
we need to translate these relapse events into
mortality events in order to compare to published
data from all screening trials. Using published
screening yield rates and knowing that survival
after relapse is approximately 2 years, we have
calculated that this putative surgery-induced
growth could explain an additional 0.11 deaths
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Figure 5 The Milan data from Fig. 3 are shown together
with the interpretation resulting from the computer sim-
ulation. The main difference between premenopausal
and postmenopausal patients is that surgery apparently
stimulates angiogenesis of dormant distant disease for
a significant fraction of premenopausal and node-positive
patients, accelerating disease by a median of two years.
184 M. Retsky et al.Control
Screened
Control
Screened
Control
Screened
Control
Screened
50 - 54 years 
of age
45 - 49 years
of age  
55 - 59 years
of age 
40
32
24
16
8
0
40
32
24
16
8
0
40
32
24
16
8
0
40
32
24
16
8
0
181614121086
Cumulative mortality  vs. Years since start of trial
40 - 44 years
of age  
42 18161412108642
Figure 6 The Health Insurance Plan (HIP) of Greater New York was the first randomized clinical trial of mammog-
raphy. These cumulative mortality data are modified from Shapiro.3 The early appearing advantage of mammography
for women aged 50e59 is seen together with the delayed advantage for women aged 40e49. A two-year shift to the
right in the mortality curve for women aged 40e49 would provide early detection advantage very similar to the 20e
30% advantage seen for women aged 50e59.per 1000 screened women aged 40e49 that occurs
in the third year after the start of screening.19 This
is approximately what is observed in trials as can be
seen in Figs. 1,7, and 8. The HIP data (Fig. 6) are
not published in a convenient format for this
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Figure 7 Five of the mammography trials were con-
ducted in Sweden. These data are the combined results
of these trials and constitute the bulk of the mammogra-
phy data. Data for women aged 40e49 are shown. The
early excess mortality for the screened population is ap-
parent beginning in the third year and continuing until
the seventh year when a clear advantage begins to
appear. In the third year, the apparent disadvantage
of screening is approximately 0.1 per 1000 screened
women aged 40e49, in agreement with calculations.
Modified from Larsson et al.5 As in Fig. 6, a two-year shift
to the right would produce 20e30% mortality advantage
for women aged 40e49.comparison, but the excess mortality is quantita-
tively the same as the other trials seen in Figs. 7
and 8.
While that excess mortality magnitude may
seem small, it is comparable to the US age
adjusted death rate from breast cancer of 0.24
per 1000 women.
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Figure 8 The Edinburgh clinical trial of mammography
is shown. This trial has been criticized for a randomiza-
tion bias. However, it still shows the same pattern as in
the HIP (New York) trial in Fig. 6 and the Swedish over-
view in Fig. 7. The disadvantage to the intervention
group is maximum in the third year and is approximately
0.1 per 1000 screened age 40e49 women. Modified from
Alexander.7 As in Figs. 6 and 7, a two-year shift to the
right would produce 20e30% mortality advantage for
women aged 40e49.
Does surgery induce angiogenesis in breast cancer? 185As an additional opportunity to compare the
computer simulation with the trial data, we note
that a two-year shift to the right of the age 40e49
screened population in Figs. 1, 6e8 would result in
mortality advantage to screening similar to what
is found in trials for women age 50e59. This is con-
sistent with the previously mentioned two-year
acceleration in disease due to termination of
dormancy in avascular micrometastases.
We proposed that the biological mechanism of
the surgical influence on the metastatic develop-
ment could be a surge of angiogenesis resulting
from the removal of inhibitors, the appearance of
growth factors or other such effect. This would
synchronize some patients to the timewhen screen-
ing begins e which might explain a subset with
homogeneous behavior in a heterogeneous disease
as seen in Fig. 2. This mechanism is proposed as an
explanation of the paradoxical mammography data
for women aged 40e49 and is consistent with the bi-
modal relapse pattern observed.
Conclusions
We have discussed a bimodal relapse pattern for
untreated breast cancer patients and the mam-
mography paradox for women age 40e49. Analysis
of these data provides indirect evidence that
surgery to remove a primary breast tumor can
induce angiogenesis of dormant distant disease.
Testing the hypotheses presented here should be
a high priority. If they prove to be correct, various
approaches could be taken to provide the full
benefit of screening to women age 40e49.
Clinical trials could be designed to test whether
premenopausal women given an antiangiogenic
drug during the critical few days before and after
surgery fared better. In addition, surgery-induced
angiogenesis in breast cancer is very likely regul-
ated by hormones since it occurs much more
frequently in premenopausal patients than in post-
menopausal patients. This strongly suggests that
hormone related interventions, of which there are
several possibilities, might prove very useful.44e48
If there is concern that an antiangiogenic treatment
after surgery could interfere with wound healing,
a hormone-based method could be a good option.
An interesting off-topic speculation resulting
from this study is a possible evolutionary based
explanation of why there is dormancy of distant
micrometastases in premenopausal women with
primary breast tumors. Before the historical ad-
vent of surgical intervention in breast cancer,49
this effect would allow a female of childbearingage with a primary breast cancer and this trait to
live an extra two years and thus have more off-
spring than if she did not have that trait.
Another off-topic subject is that our conclusions
might provide a scientific basis for the often-
debunked myth that ‘‘cancer spreads when the
air hits it’’.50 The effect we describe would make
it seem as though cancer spreads after surgery,
while of course the cancer had already spread
but only escapes long-lasting pre-angiogenic dor-
mancy as a biological sequel of surgery.
Our results suggest that the biology of early
detection is more complex than originally
thought.51,52 Early detection sometimes produces
disappointing results as seen in large clinical trials9
and community-based screening.53
The screened population is far from homoge-
nous with regard to risk and benefit of early
detection. In light of our findings, we suggest
that until this is better understood and resolved,
guidelines for early detection of breast cancer for
young women be reconsidered. At the very least,
women need to be advised of this information as
part of an informed consent to mammography.54
Well-intentioned sweeping this problem under
the rug15,55,56 has not been helpful.
More research is needed to confirm our findings.
If true, in addition to the impact on early detec-
tion, a comprehensive treatment plan for breast
cancer would probably need to take into consid-
eration the possibility that surgery could stimulate
tumor growth including inducing angiogenesis.57,58
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